Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.74 |
| ▸ | RAB9A | P51151 | 7/20 | 0.74 |
| ▸ | NPC1 | O15118 | 5/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.71 |
| ▸ | HPGD | P15428 | 6/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | TP53 | P04637 | 3/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.67 |
| ▸ | XDH | P47989 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4832045 | 0.90 | RAB9A (0.72) | MAPTRAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL7054594 | 0.89 | KDM4E (0.83) | MAPTRAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL27916248 | 0.85 | KDM4E (0.80) | MAPTRAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL29482681 | 0.85 | RAB9A (1.00) | MAPTRAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL571161 | 0.85 | RAB9A (1.00) | MAPTRAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL1675988 | 0.83 | RAB9A (0.71) | MAPTRAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL762092 | 0.83 | MAPT (1.00) | MAPTRAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL2971118 | 0.83 | XDH (0.76) | MAPTRAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL571576 | 0.82 | XDH (0.84) | MAPTRAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL5504492 | 0.82 | MAPT (0.82) | MAPTRAB9ANPC1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761513-A1 | TETRACYCLIC COMPOUNDS AS ESTROGEN LIGANDS | Wyeth (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006007503-A1 | TETRACYCLIC COMPOUNDS AS ESTROGEN LIGANDS | WYETH (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060004087-A1 | Tetracyclic compounds as estrogen ligands | WYETH (US) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004087-A1 | Tetracyclic compounds as estrogen ligands | ESR1, ESRRA, ESR2 | MAPT 3784/4885RAB9A 826/4885NPC1 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.